Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

The Impact of the 21 Gene Recurrence Score (RS) on Chemotherapy Prescribing in Estrogen Receptor Positive, Lymph Node Positive Early Stage Breast Cancer in Ireland

NCT03843346 is registered in ClinicalTrials.gov with Cancer Trials Ireland as lead sponsor.

NCT NCT03843346
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03843346 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
The Impact of the 21 Gene Recurrence Score (RS) on Chemotherapy Prescribing in Estrogen Receptor Positive, Lymph Node Positive Early Stage Breast Cancer in Ireland
Lead sponsor
Cancer Trials Ireland
Phase
Observational
Overall status
Completed
Start date
March 16, 2017
Completion date
February 2, 2021
Enrollment
87 (actual)
Sites
10

Conditions

As the registry lists them; a condition with its own page is linked.

breast cancer